Biotech company Shattuck strikes joint-venture deal with Japanese drugmaker Ono

  • Shattuck Labs and Ono Pharmaceutical have entered into a joint-venture deal
  • The deal aims to develop treatments for autoimmune and inflammatory diseases
  • Shattuck will receive an upfront payment and be eligible for milestone payments and royalties
  • Shattuck will lead research on compounds from its pipeline, selected by Ono
  • Ono will pay for Shattuck’s research and development expenses
  • Ono has the option to conduct further research and commercialization worldwide

Shattuck Labs, an Austin biotech concern, has announced a joint-venture deal with Japanese drugmaker Ono Pharmaceutical. The partnership aims to develop treatments for autoimmune and inflammatory diseases. As part of the agreement, Shattuck will receive an upfront payment and be eligible for milestone payments and royalties. Shattuck will lead the research on certain compounds from its pipeline, which will be selected by Ono. Ono will cover Shattuck’s research and development expenses. Additionally, Ono has the option to conduct further research and commercialization worldwide. This collaboration holds great potential for advancing the treatment options for patients with autoimmune and inflammatory diseases.

Public Companies: Shattuck Labs (), Ono Pharmaceutical ()
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides specific details about the joint-venture deal between Shattuck Labs and Ono Pharmaceutical, including the up-front payment, milestone payments, and royalties. It also mentions Shattuck’s line of product candidates and Ono’s agreement to pay for Shattuck’s research and development expenses. The information provided seems factual and does not contain any obvious bias or misleading information.

Noise Level: 8
Justification: The article provides relevant information about a joint-venture deal between Shattuck Labs and Ono Pharmaceutical to develop treatments for autoimmune and inflammatory diseases. It includes details about the financial terms of the deal and the responsibilities of each company. However, the article lacks scientific rigor and intellectual honesty as it does not provide any evidence or data to support the effectiveness of Shattuck’s product candidates in treating autoimmune diseases and cancer. Additionally, it does not offer any actionable insights or solutions for the reader.

Financial Relevance: Yes
Financial Markets Impacted: The joint-venture deal between Shattuck Labs and Ono Pharmaceutical may impact the biotech and pharmaceutical industries.

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses a joint-venture deal between Shattuck Labs and Ono Pharmaceutical, which has financial implications for both companies. However, there is no mention of any extreme events or their impact.

Reported publicly: www.marketwatch.com